Indivior PLC (NASDAQ:INDV) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Indivior PLC (NASDAQ:INDV) have earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $39.3333.

INDV has been the topic of several recent research reports. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. Weiss Ratings cut shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 6th.

Indivior Trading Up 0.1%

Shares of INDV opened at $38.13 on Friday. The firm has a market cap of $4.65 billion, a PE ratio of 19.55 and a beta of 0.88. Indivior has a 1-year low of $13.45 and a 1-year high of $41.00. The firm has a fifty day simple moving average of $35.28 and a two-hundred day simple moving average of $34.27.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 EPS for the quarter. The company had revenue of $317.00 million during the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%. As a group, research analysts forecast that Indivior will post 4.05 EPS for the current fiscal year.

Insider Buying and Selling

In other Indivior news, CFO Ryan Preblick sold 36,000 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the completion of the sale, the chief financial officer directly owned 284,751 shares of the company’s stock, valued at approximately $10,735,112.70. This represents a 11.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.74% of the company’s stock.

Hedge Funds Weigh In On Indivior

A number of institutional investors have recently bought and sold shares of INDV. Quarry LP purchased a new stake in Indivior in the third quarter worth about $26,000. Raymond James Financial Inc. purchased a new stake in Indivior in the second quarter worth about $26,000. Salomon & Ludwin LLC purchased a new stake in Indivior in the fourth quarter worth about $30,000. Harbor Capital Advisors Inc. increased its position in Indivior by 309.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after buying an additional 781 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its position in Indivior by 72.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after buying an additional 460 shares in the last quarter. 60.33% of the stock is owned by institutional investors.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.